在中国心力衰竭和减少排泄率的患者中使用维里西瓜特:现实世界的前性研究
Bing-Yang Zhou1,2,3, Cui-Ying Zhang4, Ying-Yi Zhang2,3
1Department of Cardiology, Tianjin University Chest Hospital, Tianjin, China.
Cardiology
|October 30, 2025
概括
在心力衰竭 (HF) 患者中使用Vericiguat,心脏喷射率降低,在真实世界的中国数据中显示心脏死亡率和HF住院率较低. 这种现实世界的证据支持传感器Guatguat的支持.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 现实世界的证据 现实世界的证据
背景情况:
- 在受控试验中,Vericiguat在改善心力衰竭 (HF) 的临床结果方面表现出有效性,减少排气分数 (HFrEF).
- 有限的现实世界数据存在于HFrEF患者的常规临床实践中 vericiguat的有效性.
研究的目的:
- 为了评估 vericiguat在减少HFrEF的中国人群的临床终点中的实际有效性.
- 为了比较与 vericiguat 和对照组治疗的患者之间的临床结果.
主要方法:
- 在2023年1月1日至12月30日期间,预计将招募207名住院的症状性HF患者,其左心室喷射分数<45%,在2023年1月1日至12月30日期间.
- 患者被分为接受药物治疗的组和对照组.
- 随访时间的中位数为11.25个月,分析包括无变Cox回归和倾向得分匹配.
主要成果:
- 与对照组相比,给予者组表现出较低的心脏死亡率和HF住院病例的发生率.
- 在无变量分析中,维里西瓜特与心脏病死亡率 (HR:0.299) 和心脏病住院 (HR:0.586) 的风险降低有关.
- 在对年龄和性别进行倾向性得分匹配后, vericiguat对心脏病死亡率的益处维持了下来.
结论:
- 这项研究提供了来自中国的第一个现实世界的证据,表明给予者瓜特的使用与HFrEF患者的临床终点降低有关.
- 这些发现与之前的随机对照试验结果一致,支持 vericiguat在现实环境中的有效性.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
909
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
909
01:22Heart Failure Drugs: Diuretics
788
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
788
01:22Heart Failure Drugs: β-Blockers
755
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
755
01:30Heart Failure V: Medical Management
208
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
208
01:26Heart Failure Drugs: Inotropic Agents
1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K
01:30Heart Failure IV: Classification and Diagnostic Evaluation
310
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
310